Market Research Logo

Antibody Drugs: Technologies and Global Markets

Antibody Drugs: Technologies and Global Markets

Report Highlights
The global market for antibody drugs reached $80.8 billion in 2016. The market should reach $114.6 billion by 2022 increasing from $84.5 billion in 2017, at a compound annual growth rate (CAGR) of 6.3% from 2017 through 2022. 

Report Includes
An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
Analyses of global market trends, with data from 2014, 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
Analysis and assessment of the therapeutic applications of mAbs in human medicine.
A look at the antibody industry as a whole, as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industries in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

Report Scope
This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.

BCC Research analyzes and makes projections for each market and its applications, the regulatory environment, new products and technological advances. Also included in the report are relevant patent analysis and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd. and Merck & Co.

The report covers the major markets of the U.S. and Europe, as well as emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.

Monoclonal antibodies are protein-based therapies/drugs that are finding use in the treatment of number of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.

The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human and humanized antibodies.

Excluded from this report are polyclonal antibodies; screening kits; and diagnostic uses of mAbs. Also excluded are research applications of mAbs and therapeutic antibodies for veterinary use.


Chapter 1: Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2: Summary and Highlights
Chapter 3: Market and Technology Background
Antibodies and Antigens
Antibody Functions
Monoclonal Antibodies
History of Monoclonal Antibodies
Advantages and Disadvantages of Monoclonal Antibodies
Types of Monoclonal Antibodies
Manufacturing Technologies of Monoclonal Antibodies
Applications of Monoclonal Antibodies
Chapter 4: Market Breakdown by Technology Type
Market by Type
Market Overview
Market Revenue
Market Share
Market by Region
Market Overview
Market Revenue
Market Share
Murine Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Human Monoclonal Antibodies
Humanized Monoclonal Antibodies
Market by Manufacturing Process
Market Overview
Market Revenue
Market Share
Market of Murine Monoclonal Antibodies by Manufacturing Process
Market Analysis of Chimeric Monoclonal Antibodies by Manufacturing Process
Market Analysis of Human Monoclonal Antibodies by Manufacturing Process
Market Analysis of Humanized Monoclonal Antibodies by Manufacturing Process
Chapter 5: Market Breakdown by Application
Market by Diseases
Market Overview
Market Revenue
Market Share
Autoimmune Disease
Solid Tumors
Lymphoma and Leukemia
Others
Chapter 6: Industry Structure
Murine Monoclonal Antibodies
Market Leaders
Market Share
Chimeric Monoclonal Antibodies
Market Leaders
Market Share
Humanized Monoclonal Antibodies
Market Leaders
Market Share
Human Monoclonal Antibodies
Market Leaders
Market Share
Chapter 7: Regulatory Aspects
New Approvals of Monoclonal Antibodies
Recalls
Safety Alerts
Chapter 8: Patent Review/ New Developments
Patent Review
Patents by Year
Patents by Type
Patents by Company
Patents by Country
Patents by Assignee
New Developments
Phase I clinical trials
Phase II clinical trials
Phase III Clinical Trials
Phase IV Clinical Trials
Mergers and Acquisitions
Chapter 9: Analysis of Market Opportunities
Technical Issues
Human anti-mouse antibody (HAMA) Problem
Factors Affecting mAb Drugs
Increasing Prevalence of Chronic Diseases
Aging Population
Price Regulation
Regulatory Approvals
Increasing Competition between Drug Makers
Advances in Manufacturing Technologies
Biosimilars
Mergers and Acquisitions
Licensing Agreements
Chapter 10: Company Profiles
Appendix: Abbreviations
About BCC Research
About BCC Research
BCC Membership
BCC Custom Research
List of Tables
Summary Table Global Market for Antibody Drugs, by Disease, Through 2022 ($ Millions)
Table 1 Evolution of Monoclonal Antibodies
Table 2 Advantages and Disadvantages of Monoclonal Antibodies
Table 3 Murine Monoclonal Antibodies
Table 4 Chimeric Monoclonal Antibodies
Table 5 Humanized Monoclonal Antibodies
Table 6 Human Monoclonal Antibodies
Table 7 Differences between Hybridoma and Recombinant Technologies
Table 8 Murine Monoclonal Antibodies and Their Applications
Table 9 Chimeric Monoclonal Antibodies and Their Applications
Table 10 Human Monoclonal Antibodies and Their Applications
Table 11 Humanized Monoclonal Antibodies and Their Applications
Table 12 Global Sales of Antibody Drugs, by Type, Through 2022 ($ Millions)
Table 13 Market Shares for Antibody Drugs, by Type, 2016 (%)
Table 14 Global Sales of Antibody Drugs, by Region, Through 2022 ($ Millions)
Table 15 Market Shares for Antibody Drugs, by Region, 2016 (%)
Table 16 Global Market for Murine Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
Table 17 Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
Table 18 Global Market for Human Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
Table 19 Global Market for Humanized Monoclonal Antibodies, by Region, Through 2022 ($ Millions) . 38
Table 20 Global Market for Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
Table 21 Market Shares for Antibody Drugs, by Manufacturing Process, 2016 (%)
Table 22 Global Market for Murine Antibody Drugs, by Manufacturing Process, Through 2022 ($ Millions)
Table 23 Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
Table 24 Global Market for Human Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
Table 25 Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
Table 26 Global Sales of Antibody Drugs, by Disease, Through 2022 ($ Millions)
Table 27 Market Shares for Antibody Drugs, by Disease, 2016 (%)
Table 28 Types of Autoimmune Diseases
Table 29 Global Market for Antibody Drugs in Autoimmune Diseases, by Type, Through 2022 ($ Millions)
Table 30 Global Market for Antibody Drugs in Autoimmune Diseases, by Region, Through 2022 ($ Millions)
Table 31 Types of Cancer by the Tissue of Origin
Table 32 Global Market for Antibody Drugs in Solid Tumors, by Type, Through 2022 ($ Millions)
Table 33 Global Market for Antibody Drugs in Solid Tumors, by Region, Through 2022 ($ Millions)
Table 34 Types of Leukemia
Table 35 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Type, Through 2022 ($ Millions)
Table 36 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Region, Through 2022 ($ Millions)
Table 37 Global Market for Antibody Drugs in Other Diseases, by Type, Through 2022 ($ Millions)
Table 38 Global Market for Antibody Drugs in Other Diseases, by Region, Through 2022 ($ Millions)
Table 39 Leading Manufacturer of Murine Monoclonal Antibodies, 2016
Table 40 Leading Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016
Table 41 Market Shares of Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016 (%)
Table 42 Leading Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016
Table 43 Market Shares of Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016 (%) . 76
Table 44 Leading Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016
Table 45 Market Shares of Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016 (%)
Table 46 New Approvals of Monoclonal Antibodies, 2014-January 2017
Table 47 Recalls, 2014-January 2017
Table 48 Safety Alerts, 2014-January 2017
Table 49 Number of Patents, by Year, 2014-January 2017
Table 50 Number of Patents, by Type, 2014-January 2017
Table 51 Number of Patents, by Company, 2014-January 2017
Table 52 Number of Patents, by Country, 2014-January 2017
Table 53 Share of Patents by Country, 2014-January 2017 (No./%)
Table 54 Number of Patents, by Assignee, 2014-January 2017
Table 55 Monoclonal Antibodies in Phase I Clinical Trials
Table 56 Monoclonal Antibodies in Phase II Clinical Trials
Table 57 Monoclonal Antibodies in Phase III Clinical Trials
Table 58 Monoclonal Antibodies in Phase IV Clinical Trials
Table 59 Mergers and Acquisitions of Top Pharmaceutical Companies, 2014-January 2017
Table 60 Abbreviations Used in the Antibody Drug Industry
List of Figures
Summary Figure Global Market for Antibody Drugs, by Disease, 2014-2022 ($ Millions)
Figure 1 Global Sales of Antibody Drugs, by Type, 2014-2022 ($ Millions)
Figure 2 Market Shares of Antibody Drugs, by Type, 2016 (%)
Figure 3 Global Sales of Antibody Drugs, by Region, 2014-2022 ($ Millions)
Figure 4 Market Shares for Antibody Drugs, by Region, 2016 (%)
Figure 5 Global Market for Murine Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
Figure 6 Global Market for Chimeric Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
Figure 7 Global Market for Human Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
Figure 8 Global Market for Humanized Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
Figure 9 Global Market for Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions) 40
Figure 10 Market Shares for Antibody Drugs, by Manufacturing Process, 2016 (%)
Figure 11 Global Market for Murine Antibody Drugs, by Manufacturing Process, 2014-2022 ($ Millions)
Figure 12 Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
Figure 13 Global Market for Human Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
Figure 14 Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
Figure 15 Global Sales of Antibody Drugs, by Disease, 2014-2022 ($ Millions)
Figure 16 Market Shares for Antibody Drugs, by Disease, 2016 (%)
Figure 17 Global Market for Antibody Drugs in Autoimmune Diseases, by Type, 2014-2022 ($ Millions)
Figure 18 Global Market for Antibody Drugs in Autoimmune Diseases, by Region, 2014-2022 ($ Millions)
Figure 19 Global Market for Antibody Drugs in Solid Tumors, by Type, 2014-2022 ($ Millions)
Figure 20 Global Market for Antibody Drugs in Solid Tumors, by Region, 2014-2022 ($ Millions)
Figure 21 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Type, 2014-2022 ($ Millions)
Figure 22 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Region, 2014-2022 ($ Millions)
Figure 23 Global Market for Antibody Drugs in Other Diseases, by Type, 2014-2022 ($ Millions)
Figure 24 Global Market for Antibody Drugs in Other Diseases, by Region, Through 2022 ($ Millions) .. 71
Figure 25 Market Shares of Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016 (%)
Figure 26 Market Shares of Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016 (%)
Figure 27 Market Share of Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016 (%)
Figure 28 Number of Patents, by Year, 2014-January 2017
Figure 29 Number of Patents, by Type, 2014-January 2017
Figure 30 Share of Patents, by Country, 2014-January 2017 (%)
Figure 31 Number of Patents, by Assignee, 2014-January 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report